David Shaw’s United Therapeutics UTHR Stock Holding History

David Shaw’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,200	Closed	-$585K	–	5090
2025 Q4	$585K	Sell	1,200 -1,600	-57%	-$745K	﹤0.01%	3853
2025 Q3	$1.17M	Buy	+2,800	New	+$942K	﹤0.01%	3359
2025 Q1	–	Sell	-1,500	Closed	-$529K	–	4778
2024 Q4	$529K	Buy	+1,500	New	+$551K	﹤0.01%	3587
2022 Q1	–	Sell	-5,600	Closed	-$1.21M	–	5959
2021 Q4	$1.21M	Buy	+5,600	New	+$1.1M	﹤0.01%	3773
2017 Q1	–	Sell	-20,000	Closed	-$2.87M	–	3624
2016 Q4	$2.87M	Hold	20,000	–	–	﹤0.01%	1740
2016 Q3	$2.36M	Hold	20,000	–	–	﹤0.01%	1803
2016 Q2	$2.12M	Hold	20,000	–	–	﹤0.01%	1896
2016 Q1	$2.23M	Hold	20,000	–	–	﹤0.01%	1811
2015 Q4	$3.13M	Hold	20,000	–	–	﹤0.01%	1788
2015 Q3	$2.63M	Hold	20,000	–	–	﹤0.01%	1891
2015 Q2	$3.48M	Buy	20,000 +10,000	+100%	+$1.8M	0.01%	1757
2015 Q1	$1.72M	Buy	+10,000	New	+$1.52M	﹤0.01%	2140
2014 Q1	–	Sell	-20,000	Closed	-$2.26M	–	4644
2013 Q4	$2.26M	Sell	20,000 -20,000	-50%	-$1.8M	﹤0.01%	2407
2013 Q3	$3.15M	Buy	+40,000	New	+$2.92M	0.01%	2024

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

David Shaw's UTHR Position: Q2 2026 in Review

David Shaw sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 99,106 shares — an estimated $58.8M sold.

David Shaw first reported a position in UTHR in Q4 2013 and held it in 48 quarters. The position peaked at $150M in Q4 2025. 874 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

David Shaw reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
David Shaw sold 99,106 United Therapeutics shares in Q2 2026, an estimated $58.8M.
David Shaw first reported a position in United Therapeutics in Q4 2013 and held it in 48 quarters.
David Shaw's United Therapeutics position peaked at $150M in Q4 2025.
874 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.